0 item(s)
View cart
You have no items in your shopping cart.
Product Information
| Protein sequence | A DNA sequence encoding the human VEGF165 (NP_001165097.1) was expressed with a polyhistidine tag at the C-terminus |
| Expression Host | HEK293 Cells |
| QC Testing Purity | > 90 % as determined by SDS-PAGE |
| Activity | Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC). The expected ED50 for this effect is ≤ 20 ng/mL |
| Endotoxin Level | < 0.1 EU per μg of the protein as determined by the LAL method |
| Molecular Mass | The Recombinant Human VEGF165 consists of 193 amino acids and predicts a molecular mass of 22.3 kD |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 6% mannitol are added as protectants before lyophilization |
| Stability & Storage | 24 months at 2 °C to 8 °C in lyophilized state. 6 months at -20 °C under sterile conditions after reconstitution. 12 months at -80 °C under sterile conditions after reconstitution. Recommend to aliquot the protein into smaller quantities after reconstituting with water for injection, normal saline or PBS, and keep the diluted concentration above 100 µg/mL. Avoid repeated freeze-thaw cycles. |
Background
VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; FMS-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product.
References
-
Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
-
Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
-
Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
Document
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
No data
